Titre : Vinblastine

Vinblastine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Patient Participation

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?

La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués.
Vinblastine Cancer Diagnostic médical
#2

Quels tests précèdent l'administration de vinblastine ?

Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement.
Tests de laboratoire Imagerie médicale Vinblastine

Symptômes 2

#1

Quels sont les effets secondaires courants de la vinblastine ?

Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux.
Effets secondaires Vinblastine Nausées
#2

La vinblastine provoque-t-elle des douleurs ?

Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique.
Douleur Vinblastine Effets indésirables

Prévention 2

#1

La vinblastine a-t-elle un rôle préventif dans le cancer ?

Non, la vinblastine est un traitement et ne prévient pas le développement du cancer.
Prévention du cancer Vinblastine Traitement
#2

Peut-on prévenir les effets secondaires de la vinblastine ?

Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine.
Effets secondaires Vinblastine Médicaments antiémétiques

Traitements 2

#1

Dans quels types de cancer la vinblastine est-elle utilisée ?

Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule.
Lymphome Cancer du poumon Vinblastine
#2

Comment la vinblastine est-elle administrée ?

La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale.
Administration intraveineuse Vinblastine Traitement du cancer

Complications 2

#1

Quelles complications peuvent survenir avec la vinblastine ?

Des complications incluent des infections, des saignements et des problèmes neurologiques.
Complications Vinblastine Infections
#2

La vinblastine peut-elle affecter la moelle osseuse ?

Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs.
Moelle osseuse Vinblastine Dépression médullaire

Facteurs de risque 2

#1

Qui est à risque d'effets indésirables avec la vinblastine ?

Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru.
Facteurs de risque Vinblastine Maladies cardiaques
#2

Les enfants peuvent-ils prendre de la vinblastine ?

Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance.
Vinblastine Pédiatrie Traitement du cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vinblastine : Questions médicales les plus fréquentes", "headline": "Vinblastine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vinblastine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-10", "dateModified": "2025-05-05", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vinblastine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca", "url": "https://questionsmedicales.fr/mesh/D014748", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827" } } }, "about": { "@type": "MedicalCondition", "name": "Vinblastine", "alternateName": "Vinblastine", "code": { "@type": "MedicalCode", "code": "D014747", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Christine Chevreau", "url": "https://questionsmedicales.fr/author/Christine%20Chevreau", "affiliation": { "@type": "Organization", "name": "Department of Medicine, Oncopole, Toulouse, France." } }, { "@type": "Person", "name": "Stéphane Culine", "url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Culine", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr." } }, { "@type": "Person", "name": "Gwenaelle Gravis", "url": "https://questionsmedicales.fr/author/Gwenaelle%20Gravis", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France." } }, { "@type": "Person", "name": "Florence Joly", "url": "https://questionsmedicales.fr/author/Florence%20Joly", "affiliation": { "@type": "Organization", "name": "Department of Medical Oncology, François Baclesse Cancer Center, Caen, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Haemodialysis patient's adherence to treatment: Relationships among nurse-patient-initiated participation and nurse's attitude towards patient participation.", "datePublished": "2022-07-19", "url": "https://questionsmedicales.fr/article/35854651", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jocn.16449" } }, { "@type": "ScholarlyArticle", "name": "Development and validation of a patient participation scale.", "datePublished": "2023-02-22", "url": "https://questionsmedicales.fr/article/36814372", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/jan.15593" } }, { "@type": "ScholarlyArticle", "name": "Increasing patient participation in oncology clinical trials.", "datePublished": "2022-08-31", "url": "https://questionsmedicales.fr/article/36043431", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cam4.5150" } }, { "@type": "ScholarlyArticle", "name": "The effects of a mobile application for patient participation to improve patient safety.", "datePublished": "2022-05-11", "url": "https://questionsmedicales.fr/article/35543141", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/hex.13503" } }, { "@type": "ScholarlyArticle", "name": "Patient Engagement in Health Research: Perspectives from Patient Participants.", "datePublished": "2023-02-26", "url": "https://questionsmedicales.fr/article/36975423", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/curroncol30030210" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" }, { "@type": "ListItem", "position": 10, "name": "Vinblastine", "item": "https://questionsmedicales.fr/mesh/D014747" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vinblastine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vinblastine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vinblastine", "description": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?\nQuels tests précèdent l'administration de vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Patient+Participation#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vinblastine", "description": "Quels sont les effets secondaires courants de la vinblastine ?\nLa vinblastine provoque-t-elle des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Patient+Participation#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vinblastine", "description": "La vinblastine a-t-elle un rôle préventif dans le cancer ?\nPeut-on prévenir les effets secondaires de la vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Patient+Participation#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vinblastine", "description": "Dans quels types de cancer la vinblastine est-elle utilisée ?\nComment la vinblastine est-elle administrée ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Patient+Participation#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vinblastine", "description": "Quelles complications peuvent survenir avec la vinblastine ?\nLa vinblastine peut-elle affecter la moelle osseuse ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Patient+Participation#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vinblastine", "description": "Qui est à risque d'effets indésirables avec la vinblastine ?\nLes enfants peuvent-ils prendre de la vinblastine ?", "url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Patient+Participation#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués." } }, { "@type": "Question", "name": "Quels tests précèdent l'administration de vinblastine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants de la vinblastine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux." } }, { "@type": "Question", "name": "La vinblastine provoque-t-elle des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique." } }, { "@type": "Question", "name": "La vinblastine a-t-elle un rôle préventif dans le cancer ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Non, la vinblastine est un traitement et ne prévient pas le développement du cancer." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires de la vinblastine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine." } }, { "@type": "Question", "name": "Dans quels types de cancer la vinblastine est-elle utilisée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule." } }, { "@type": "Question", "name": "Comment la vinblastine est-elle administrée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la vinblastine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des saignements et des problèmes neurologiques." } }, { "@type": "Question", "name": "La vinblastine peut-elle affecter la moelle osseuse ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs." } }, { "@type": "Question", "name": "Qui est à risque d'effets indésirables avec la vinblastine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru." } }, { "@type": "Question", "name": "Les enfants peuvent-ils prendre de la vinblastine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 05/05/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Eric Bouffet

2 publications dans cette catégorie

Affiliations :
  • Programme in Developmental and Stem Cell Biology, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.

Yaser Hassan Dewir

2 publications dans cette catégorie

Affiliations :
  • Plant Production Department, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia.

Sarah E O'Connor

2 publications dans cette catégorie

Affiliations :
  • Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology, Jena, Germany.

G A Amos Burke

2 publications dans cette catégorie

Affiliations :
  • Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.

Riccardo Finotello

2 publications dans cette catégorie

Affiliations :
  • Department of Small Animal Clinical Sciences, Department of Veterinary Anatomy Physiology and Pathology, Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Chester High Rd, Neston CH64 7TE, UK.

Yoshihiro Nishida

2 publications dans cette catégorie

Affiliations :
  • Department of Rehabilitation Medicine, Nagoya University Hospital, Nagoya, Japan.
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Shunsuke Hamada

2 publications dans cette catégorie

Affiliations :
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Tomohisa Sakai

2 publications dans cette catégorie

Affiliations :
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Hiroshi Koike

2 publications dans cette catégorie

Affiliations :
  • Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.

Magdalena Markowicz-Piasecka

2 publications dans cette catégorie

Affiliations :
  • Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland; Department of Applied Pharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland.

Sources (10000 au total)

Haemodialysis patient's adherence to treatment: Relationships among nurse-patient-initiated participation and nurse's attitude towards patient participation.

To evaluate the relationship between nurse-patient-initiated participation, nurses' attitudes towards patient's participation, and patients' adherence to treatment. Specifically, to (1) explore nurse-... To improve haemodialysis patients' health, it is crucial to identify nurses' and patients' factors facilitating adherence to treatment.... An exploratory-sequential mixed-methods (quantitative and qualitative) design.... All nurses working at a dialysis ward (n = 30) and their randomly selected patients (n = 102) participated. Qualitative data on nurse-patient-initiated participation were derived from transcribed nurs... Content analysis of the conversations indicated that nurse-initiated participation focused on patient's medical condition, treatment plan and education; while patients initiated more small talk. Non-a... The findings provided paradoxical insights: Nurses' positive attitudes towards participation lead them to accept the patient's position for shortening haemodialysis treatment, so that adherence to car... Nurses require education on negotiating methods to help achieve patient adherence while respecting the patient's opinion. Patients should be educated how to approach nurses, seeking the information th...

Development and validation of a patient participation scale.

To develop an instrument measuring patient participation in healthcare and verify the validity and reliability of the patient participation scale (PPS).... A methodological study using instrument-development and instrument-verification phases.... Data were collected from January to August 2021. The instrument-development phase identified preliminary items through literature reviews and interviews with 17 patients and nine healthcare providers.... The PPS comprised 21 items divided into four themes: 'sharing of information and knowledge', 'performing proactive self-management activities', 'establishing mutual trust relationships' and 'partaking... The PPS can reasonably and reliably measure the participation levels that patients experience in their treatment and care process.... This PPS can help nurses encourage internal medicine patients to participate in their treatment and care....

Increasing patient participation in oncology clinical trials.

Timely recruitment of eligible participants is essential for the success of clinical trials, with insufficient accrual being the leading cause for premature termination of both oncology and non-oncolo... In this paper we further elaborate on the challenges for patient participation in oncology trials from physician, patient, healthcare system, and some trial-related perspectives.... We present strategies such as use of digital healthcare technologies, real-world data and real-world evidence, decentralized clinical trials, pragmatic trial designs, and supportive services to increa... Multifaceted measures are necessary to increase patient participation, especially for those who are under-represented in cancer trials....

The effects of a mobile application for patient participation to improve patient safety.

Patient participation in patient safety activities in care processes is a fundamental element of safer care. Patients play an important role in preventing patient safety incidents and improving health... This study aimed to develop a mobile application for health consumers' participation and evaluate the effect of the mobile application on improving health consumers' participation in patient safety.... A quasi-experimental design was adopted. We developed a mobile application on the basis of a needs assessment, literature review, compilation of patient safety topics, and validity testing of the appl... The intervention group (n = 60) had significantly higher overall average scores than the control group (n = 37) with regard to patient safety knowledge (p < .001), self-efficacy of participation (p = ... This study demonstrated that educating health consumers through a mobile application with useful information improves patient participation in patient safety activities. Educational materials and pati... Patients were involved during the programme development and evaluation....

Patient Engagement in Health Research: Perspectives from Patient Participants.

Over the past decade, patient engagement (PE) has emerged as an important way to help improve the relevance, quality, and impact of health research. However, there is limited consensus on how best to ... A qualitative approach was used to gather reflections from members of the Patient Advisory Committee regarding their experiences in participating in a research study over six years. Each member comple... Our reflections about experiences as a PAC on a large, pan-Canadian research study include three overarching topics (1) what worked well; (2) areas for improvement; and (3) reflections on our overall ... Engaging individuals who have experienced the types of events which are the focus of a research study can contribute to the overall relevance of the project. However, intentional efforts are necessary...

Questionnaires measuring patient participation in patient safety-A systematic review.

The purpose of this review was to evaluate the content, validity and reliability of patient-reported questionnaires on patient participation in patient safety.... Patient participation in patient safety is one of the key strategies that are increasingly regarded as a critical intervention to improve the quality of safety care.... A systematic review was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The content, reliability and validity of patient-reported questio... Twenty-seven studies were included for data extraction and synthesis. The questionnaire contents most commonly used to describe patient participation in patient safety were 'attitudes and perceptions'... Future research targeting the different safety issues is still indispensable for developing patient-reported questionnaires with great psychometric quality in validity, reliability, feasibility and us... Clinical nurses should consider the internal consistency, test-retest reliability, content validity and structural validity of the questionnaires that have been positively appraised for methodological...

Patient preferences and experiences of participation in surgical cancer care.

Quality cancer care necessitates opportunities for patient participation, supposedly recognizing the individual's preferences and experiences for being involved in their health and healthcare issues. ... To explore preference-based patient participation in surgical cancer care.... A cross-sectional study was conducted. The Patient Preferences for Patient Participation tool (4Ps) was used, which includes 12 attributes of preferences for and experiences of patient participation. ... The results are based on a total of 101 questionnaires. Having reciprocal communication and being listened to by healthcare staff were commonly deemed crucial for patient participation. While 60% of t... To support person-centered surgical care, further efforts to suffice preference-based participation are needed, including opportunities for patients to share their experiences and engage in the planni...

Patient participation in surgical site infection prevention: perceptions of nurses, physicians and patients.

To analyze the perception of patients and health professionals regarding patients' participation in surgical site infection prevention.... Cross-sectional study conducted in two hospitals in the city of São Paulo, with a convenience sample of 123 patients in the postoperative period of elective surgeries and 92 health professionals (phys... Patients (78.9%) and professionals (79.4%) fully agreed with the importance of patient participation to prevent surgical site infection. The impact of patient participation on infection rates was sign... Patients and health professionals believe that patient participation in surgical site infection prevention is important....

Actions for mitigating the negative effects of patient participation in patient safety: a qualitative study.

Recent research within the context of Obstetrics shows the added value of patient participation in in-hospital patient safety. Notwithstanding these benefits, recent research within an Obstetrics depa... This study was conducted in the Obstetrics Department of a tertiary academic center. An explorative qualitative interview study included sixteen interviews with professionals (N = 8) and patients (N =... Eighteen actions were identified that mitigated the negative effects of patient participation in patient safety within an Obstetrics department. These actions were categorized into five themes: 'struc... Most of the identified actions are linked to changing the culture to generate more patient-centered care and change the current reality, which looks predominantly from the perspective of the professio...